Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

MLTX

MoonLake Immunotherapeutics

Jan 20 • 09:43AM ET

16.94

+0.18 1.07 %

Healthcare • Biotechnology • Switzerland • NASD

Peers: AMGN VRTX REGN ALNY BIIB BMRN GILD INCY SRPT BLUE

| Held by: ESML VHT SBIO ONEQ NUSC BBC VT FHLC FMED ESGV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.33	Insider Own	10.89%	Shs Outstand	63.70M	Perf Week	-6.36%
Market Cap	1.21B	Forward P/E	-	EPS next Y	-3.61	Insider Trans	-47.00%	Shs Float	63.13M	Perf Month	21.43%
Enterprise Value	906.61M	PEG	-	EPS next Q	-0.99	Inst Own	60.02%	Short Float	9.15%	Perf Quarter	85.75%
Income	-210.50M	P/S	-	EPS this Y	-89.50%	Inst Trans	-27.04%	Short Ratio	2.19	Perf Half Y	-68.38%
Sales	0.00M	P/B	3.74	EPS next Y	-0.77%	ROA	-45.14%	Short Interest	5.78M	Perf YTD	28.53%
Book/sh	4.54	P/C	3.18	EPS next 5Y	-21.23%	ROE	-54.18%	52W High	62.75 -73.00%	Perf Year	-59.15%
Cash/sh	5.33	P/FCF	-	EPS past 3/5Y	34.85% -319.65%	ROIC	-57.97%	52W Low	5.95 184.71%	Perf 3Y	42.47%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.11% 7.49%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-157.74%	Oper. Margin	-	ATR (14)	1.24	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.50	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	60.44	Recom	2.18
Dividend Gr. 3/5Y	- -	Current Ratio	8.50	EPS Q/Q	-95.56%	SMA20	17.04%	Beta	1.20	Target Price	20.28
Payout	-	Debt/Eq	0.26	Sales Q/Q	-	SMA50	22.76%	Rel Volume	0.42	Prev Close	16.76
Employees	100	LT Debt/Eq	0.26	Earnings	Nov 05 BMO	SMA200	-49.61%	Avg Volume	2.64M	Price	16.94
IPO	Oct 20, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-25.17% -	Trades		Volume	91,040	Change	1.07%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-15-26	Downgrade	Goldman	Neutral → Sell	$10
Jan-09-26	Upgrade	BTIG Research	Neutral → Buy	$24
Nov-03-25	Upgrade	H.C. Wainwright	Neutral → Buy	$30
Oct-02-25	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-01-25	Downgrade	Goldman	Buy → Neutral	$7
Sep-30-25	Downgrade	Wolfe Research	Outperform → Underperform	$2
Sep-30-25	Downgrade	Citigroup	Buy → Neutral	$5
Sep-29-25	Downgrade	Stifel	Buy → Hold	$13
Sep-29-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$10
Sep-29-25	Downgrade	Jefferies	Buy → Hold	$8
Sep-29-25	Downgrade	BTIG Research	Buy → Neutral
Jul-28-25	Initiated	Rothschild & Co Redburn	Neutral	$65
May-19-25	Upgrade	Wolfe Research	Peer Perform → Outperform	$61
Mar-18-25	Initiated	RBC Capital Mkts	Outperform	$67
Jan-17-25	Upgrade	Goldman	Neutral → Buy	$62 → $82
Nov-05-24	Resumed	Wedbush	Outperform	$92 → $73
Aug-26-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-25-24	Initiated	Oppenheimer	Outperform	$104
Apr-02-24	Initiated	Goldman	Neutral	$62
Feb-15-24	Initiated	Wolfe Research	Outperform	$77

Show Previous Ratings

Jan-15-26 04:33PM	Stocks Boosted by Chip Demand Optimism (Barchart) -6.09%
Jan-09-26 06:28AM	Insmeds ginormous lung drug sales; J&Js US pricing deal (BioPharma Dive) +28.94%
Jan-08-26 10:19AM	MoonLake Catapults On FDA Deal For Its Down-And-Out Skin Disease Drug (Investor's Business Daily) +27.02%
02:06PM	MoonLake Says FDA May Allow Skin Drug Filing Without New Trials, Stock Soars (Benzinga)
08:00AM	MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day (GlobeNewswire)
12:00PM	Loading…
Dec-15-25 12:00PM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights MLTX (Business Wire)
Dec-11-25 08:01AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX (PR Newswire)
Dec-09-25 09:00AM	Investors in MoonLake Immunotherapeutics Should Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX (PR Newswire)
Dec-08-25 02:26AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX (PR Newswire)
Dec-03-25 03:05PM	MoonLake's (MLTX) SLK Efficacy Claims Under Scrutiny After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority- Hagens Berman (PR Newswire) +6.63%
Dec-02-25 09:00AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX (PR Newswire) -5.51%
Dec-01-25 08:38PM	MLTX Lawsuit: Hagens Berman Scrutinizing MoonLake's SLK Efficacy Claims After 90% Plunge; Focus on Nanobody vs. BIMZELX Superiority (PR Newswire)
03:18PM	MLTX SHAREHOLDERS: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15 (Newsfile)
04:25AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX (PR Newswire)
Nov-27-25 02:16PM	MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman (Newsfile)
08:50AM	Loading…
Nov-26-25 08:50AM	MoonLake Immunotherapeutics' (MLTX) Stock Crashes 90%, Triggers Lawsuit After Reported Phase 3 Trial Data for Sole Drug Candidate -- Hagens Berman (PR Newswire)
Nov-25-25 04:31PM	MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit -- Hagens Berman (PR Newswire)
Nov-21-25 08:45AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MLTX (PR Newswire)
Nov-14-25 09:00AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX (PR Newswire)
Nov-11-25 04:25AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX (PR Newswire) +8.60%
Nov-07-25 02:49AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX (PR Newswire)
Nov-05-25 07:11AM	MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering (GlobeNewswire)
07:00AM	MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody Sonelokimab (GlobeNewswire)
Oct-29-25 08:46AM	MLTX STOCK LOSS NOTICE: MoonLake Immunotherapeutics Investors are Notified they may have been Affected by Fraud and are Urged to Contact BFA Law (Newsfile)
Oct-28-25 08:55AM	Investors in MoonLake Immunotherapeutics (MLTX): Protect Your Rights - Contact Levi & Korsinsky Before December 15, 2025 (Newsfile)
Oct-22-25 05:47PM	The Best AI for Picking Stocks, Ranked by Performance (MarketBeat)
Oct-16-25 03:14AM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MLTX (PR Newswire) -5.16%
Oct-15-25 03:41PM	MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights MLTX (Business Wire)
Oct-14-25 12:03PM	MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman (PR Newswire)
Oct-01-25 08:12AM	MoonLake Immunotherapeutics (MLTX) Faces Investor Scrutiny After Reporting Disappointing Phase 3 Trial Data For Lead Drug Candidate -- Hagens Berman (PR Newswire)
05:30PM	Loading…
Sep-29-25 05:30PM	Podcast: U.S. Stocks Tick Higher as Government Shutdown Looms (The Wall Street Journal) -89.93% +14.81%
11:46AM	Applovin, furniture stocks, MoonLake: Trending Tickers (Yahoo Finance Video)
09:42AM	UCB Soars to Record as Rival MoonLake Crashes on Trial Data (Bloomberg)
09:38AM	MoonLake Crashes 89% On Mixed Results For Skin Disease Treatment (Investor's Business Daily)
08:40AM	MoonLake Immunotherapeutics Stock Collapses. Why It's Down 88%. (Barrons.com)
Sep-28-25 12:04PM	MoonLake Immunotherapeutics reports on week 16 results of the VELA Phase 3 hidradenitis suppurativa program with the Nanobody sonelokimab (GlobeNewswire)
Sep-10-25 12:59AM	Leerink Partners Reiterated a Buy on MoonLake Immunotherapeutics (MLTX) (Insider Monkey)
Aug-27-25 03:32AM	2 Small-Cap Biotech Stocks Well Positioned for a Breakout (Motley Fool)
Aug-16-25 10:41PM	MoonLake Immunotherapeutics (MLTX): A Bull Case Theory (Insider Monkey)
Aug-05-25 07:00AM	MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Jul-31-25 12:33PM	Phase 3 Trials Accelerate MoonLake Advances for Immunologic Disease Treatment (Insider Monkey)
Jul-09-25 01:09AM	Merck nears about $10 billion deal for London-based lung therapy firm Verona, FT reports (Reuters)
Jun-04-25 12:06PM	MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout (Zacks) +5.15%
Jun-03-25 09:33AM	Constellation and Meta, Merck, Snowflake: Trending Tickers (Yahoo Finance Video) +17.95%
09:32AM	MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover (Investor's Business Daily)
09:27AM	MoonLake Immunotherapeutics Catapults On Rumored $3 Billion Merck Takeover Bid (Investor's Business Daily)
07:38AM	Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report (Benzinga)
07:20AM	MoonLake Stock Jumps 23%. Why a $3 Billion Merck Offer Could Be a Win-Win. (Barrons.com)
Jun-02-25 05:08PM	Merck held talks to buy biotech MoonLake for over $3 billion, FT reports (Reuters) +5.51%
May-27-25 03:33PM	H.C. Wainwright Maintains Buy Rating on MoonLake Immunotherapeutics (MLXT), Keeps PT (Insider Monkey)
May-15-25 09:55AM	Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet (Zacks)
May-12-25 04:00PM	MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-25-25 04:05PM	MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 (GlobeNewswire)
Apr-23-25 12:52PM	Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
Apr-08-25 03:31AM	MoonLake Immunotherapeutics: A Buy At Dips (Seeking Alpha) -5.59%
Apr-03-25 07:00AM	MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates (GlobeNewswire)
Feb-26-25 07:00AM	MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-25-25 09:49AM	Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now? (Insider Monkey)
Feb-23-25 01:33PM	MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts (Insider Monkey)
Feb-20-25 12:12PM	MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now (Insider Monkey)
Jan-10-25 07:15AM	MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG (TipRanks)
Jan-08-25 07:00AM	MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody sonelokimab (GlobeNewswire)
Nov-13-24 08:00AM	MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody sonelokimab in patients with active psoriatic arthritis (GlobeNewswire)
Nov-07-24 07:00AM	MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Oct-08-24 09:11PM	Biotechnology Value Fund L.P. Reduces Stake in MoonLake Immunotherapeutics (GuruFocus.com)
Sep-24-24 11:55PM	Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now? (Insider Monkey) -6.36%
Sep-23-24 02:44AM	MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock (Insider Monkey)
Sep-09-24 07:00AM	MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11 (GlobeNewswire)
Aug-27-24 08:21PM	MoonLake Immunotherapeutics (MLTX): One of Oppenheimers Top Stock Picks For the Next 12 Months (Insider Monkey)
Aug-07-24 08:00AM	MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 (GlobeNewswire)
Jun-10-24 08:00AM	MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody sonelokimab in Psoriatic Arthritis (GlobeNewswire)
May-16-24 08:00AM	MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (GlobeNewswire)
May-07-24 09:02PM	MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes (GuruFocus.com)
01:53PM	MLTX Stock Earnings: MoonLake Misses EPS for Q1 2024 (InvestorPlace)
10:15AM	MoonLake Immunotherapeutics Q1 Net Loss Widens (MT Newswires)
08:00AM	MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-10-24 07:00AM	MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions (GlobeNewswire)
Mar-11-24 04:25PM	MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test (Investor's Business Daily)
Mar-10-24 12:00PM	MoonLake announces significant improvements with Nanobody sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day (GlobeNewswire)
Mar-04-24 08:00AM	MoonLake Immunotherapeutics to present MIRA trial data of Nanobody sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 (GlobeNewswire)
Mar-01-24 12:38AM	Insider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX) (GuruFocus.com) +5.56%
Feb-29-24 08:00AM	MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 (GlobeNewswire) -15.09%
Feb-26-24 08:00AM	MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody sonelokimab (SLK) in Hidradenitis Suppurativa (HS) (GlobeNewswire)
Feb-20-24 11:44PM	Insider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake Immunotherapeutics (GuruFocus.com) -7.88%
Jan-11-24 09:55AM	Wall Street Analysts Believe MoonLake Immunotherapeutics (MLTX) Could Rally 26.97%: Here's is How to Trade (Zacks)
Jan-10-24 08:42AM	Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now? (Zacks)
Dec-22-23 03:01PM	CFO Matthias Bodenstedt Sells 100,000 Shares of MoonLake Immunotherapeutics (GuruFocus.com)
Nov-14-23 12:13PM	MoonLake Immunotherapeutics (MLTX) Posts Q3 2023 Results: Clinical Progress Amid Controlled Expenses (GuruFocus.com)
08:00AM	MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-06-23 04:03PM	Why Former Highflier MoonLake Plummeted 29% After A Recent Run (Investor's Business Daily) -29.11% +15.98%
09:46AM	Top-Rated MoonLake Stock Crashes On Mixed Test Results For Arthritis Drug (Investor's Business Daily)
Nov-05-23 11:00AM	MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody sonelokimab in active psoriatic arthritis (GlobeNewswire)
Oct-26-23 10:33AM	12 Best Performing NASDAQ Stocks in 2023 (Insider Monkey)
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey)
Oct-16-23 04:30PM	MoonLake Immunotherapeutics' Lead Skin Disorder Candidate Continues to Deliver on Best-Efficacy Profile: Analyst (Benzinga) +10.72% -5.20%
04:04PM	Why Top-Notch MoonLake Surged 11% And Almost Broke Out (Investor's Business Daily)
10:41AM	Why Top 1% Biotech MoonLake Just Surged Within Striking Distance Of A Breakout (Investor's Business Daily)
Oct-15-23 09:03AM	MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa (GlobeNewswire)
Oct-11-23 10:15AM	MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress (GlobeNewswire) -7.06%
Oct-04-23 07:01AM	Phase 2 MIRA primary analysis trial results (12-week) for MoonLake's Nanobody sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress (GlobeNewswire)

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Santos da Silva Jorge	Chief Executive Officer	Dec 08 '25	Sale	15.08	130,000	1,960,400	2,948,577	Dec 10 04:29 PM
Santos da Silva Jorge	Chief Executive Officer	Dec 09 '25	Sale	14.49	70,000	1,014,300	2,878,577	Dec 10 04:29 PM
Reich Kristian	Chief Scientific Officer	Dec 08 '25	Sale	15.08	130,000	1,960,400	72,908	Dec 10 04:29 PM
Reich Kristian	Chief Scientific Officer	Dec 09 '25	Sale	14.43	72,908	1,052,062	0	Dec 10 04:29 PM
Jorge Pedro Santos Radeck Da S	Officer	Dec 08 '25	Proposed Sale	14.90	200,000	2,980,000		Dec 08 10:36 AM
Kristian Dieter Johannes Reich	Officer	Dec 08 '25	Proposed Sale	14.80	202,908	3,003,038		Dec 08 10:07 AM
Bodenstedt Matthias	Chief Financial Officer	Oct 08 '25	Buy	9.09	10,870	98,808	627,536	Oct 09 09:01 AM
Chen Bihua	Former 10% Owner	Sep 29 '25	Sale	7.21	6,494,151	46,827,628	2,000,000	Oct 01 05:22 PM
Chen Bihua	Former 10% Owner	Sep 30 '25	Sale	6.96	5,827	40,556	1,994,173	Oct 01 05:22 PM
Moukheibir Catherine	Director	Jul 03 '25	Option Exercise	0.00	23,500	0	23,500	Jul 07 04:03 PM
Moukheibir Catherine	Director	Jul 03 '25	Sale	48.79	23,500	1,146,565	0	Jul 07 04:03 PM
Moukheibir Catherine	Director	Jul 03 '25	Proposed Sale	48.79	23,500	1,146,595		Jul 03 01:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MLTX

MoonLake Immunotherapeutics

Upgrade your FINVIZ experience